Physician profile
Brad S Lerner
NPI 1235288184
$3,118.18
in general payments reported to CMS, 2019-2025
33 companies · $820 in 2025
The $820 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $138 · 2021: $156 · 2022: $448 · 2023: $517 · 2024: $652 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.25 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $461.70 | 2019-2025 | Prolia, Evenity, Prolia |
| Novo Nordisk INC | $374.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $309.22 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.23 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $233.59 | 2022-2024 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $169.69 | 2022-2025 | |
| Abbvie INC. | $151.85 | 2023 | |
| Lilly USA, LLC | $148.89 | 2023-2025 | Mounjaro, Kisunla, Zepbound |
| Radius Health, INC. | $121.36 | 2019-2022 | |
| Janssen Biotech, INC. | $76.98 | 2021 | |
| Astellas Pharma US INC | $74.92 | 2020-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $68.59 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $66.77 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $66.36 | 2024-2025 | Gemtesa |
| Sanofi Pasteur INC. | $61.91 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $57.45 | 2023-2024 | |
| Shield Therapeutics INC | $46.12 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $44.61 | 2025 | Edarbi |
| Glaxosmithkline, LLC. | $37.81 | 2022-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $35.21 | 2021-2024 | Breztri |
| Corium, LLC | $22.88 | 2022 | |
| Hikma Pharmaceuticals USA | $22.82 | 2020 | |
| Optinose US, INC. | $22.14 | 2022 | |
| Eisai INC. | $20.53 | 2024 | |
| Arbor Pharmaceuticals, INC. | $16.25 | 2022 | |
| Lucid Diagnostics INC. | $16.23 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.24 | 2022 | |
| Merck Sharp & Dohme LLC | $14.12 | 2025 | Vaxneuvance |
| Alfasigma USA, INC. | $13.92 | 2020 | |
| Tactile Systems Technology INC | $13.20 | 2020 | |
| Therapeuticsmd, INC. | $12.74 | 2019 | |
| Allergan, INC. | $11.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.